{'fraction_non_alphanumeric': 0.03160270880361174, 'fraction_numerical': 0.015048908954100828, 'mean_word_length': 5.519607843137255, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Secukinumab: A complete approach to psoriatic patients—Real‐world evidence study

Dear Editor, Psoriasis is a chronic and debilitating immune-mediated inflammatory disease, associated with an increased risk for comorbidities and a substantial psychologic and socioeconomic impact that can last a lifetime, for which secukinumab has demonstrated high efficacy and a very favorable safety profile in several real-world studies. This retrospective single-center cohort study collected data from 66 patients treated with secukinumab up to 40 weeks in a real-world setting, and evaluated secukinumab drug survival, effectiveness and safety profile. The study population consisted of consecutive moderate to severe plaque psoriasis (PsO) patients, with or without psoriatic arthritis (PsA), attending one Psoriasis Clinic in Lisbon, Portugal, who were treated with secukinumab. This study was conducted according to the tenets of the Declaration of Helsinki. Effectiveness outcomes include psoriasis area and severity index (PASI). Each score was assessed at week 0 (baseline), 4, 8 to 10, 16, 20 to 24 and 40. The safety profile of secukinumab was also evaluated. Nonparametric statistical methods were used. A P < .05 (two-sided) was considered statistically significant. TABLE 1 Baseline clinical characteristics of the total cohort